Journal of Cachexia, Sarcopenia and Muscle最新文献

筛选
英文 中文
Kidney function in cachexia and sarcopenia: Facts and numbers 恶病质和肌肉减少症的肾功能:事实和数字
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-24 DOI: 10.1002/jcsm.13260
Masatsugu Okamura, Masaaki Konishi, Javed Butler, Kamyar Kalantar-Zadeh, Stephan von Haehling, Stefan D. Anker
{"title":"Kidney function in cachexia and sarcopenia: Facts and numbers","authors":"Masatsugu Okamura,&nbsp;Masaaki Konishi,&nbsp;Javed Butler,&nbsp;Kamyar Kalantar-Zadeh,&nbsp;Stephan von Haehling,&nbsp;Stefan D. Anker","doi":"10.1002/jcsm.13260","DOIUrl":"https://doi.org/10.1002/jcsm.13260","url":null,"abstract":"<p>Cachexia, in the form of unintentional weight loss &gt;5% in 12 months or less, and secondary sarcopenia in the form of muscle wasting are serious conditions that affect clinical outcomes. A chronic disease state such as chronic kidney disease (CKD) often contributes to these wasting disorders. The purpose of this review is to summarize the prevalence of cachexia and sarcopenia, their relationship with kidney function, and indicators for evaluating kidney function in patients with CKD. It is estimated that approximately half of all persons with CKD will develop cachexia with an estimated annual mortality rate of 20%, but few studies have been conducted on cachexia in CKD. Hence, the true prevalence of cachexia in CKD and its effects on kidney function and patient outcomes remain unclear. Some studies have highlighted the concept of protein-energy wasting (PEW) which usually include sarcopenia and cachexia. Several studies have examined kidney function and CKD progression in patients with sarcopenia. Most studies use serum creatinine levels to estimate kidney function. However, creatinine may be influenced by muscle mass, and creatinine-based glomerular filtration rate may overestimate kidney function in patients with reduced muscle mass or muscle wasting. Cystatin C, which is least affected by muscle mass, has been used in some studies, and creatinine-to-cystatin-C ratio has emerged as an important prognostic marker. A previous study incorporating 428 320 participants reported that participants with CKD and sarcopenia had a 33% higher hazard of mortality compared with those without (7% to 66%, <i>P</i> = 0.011), and that those with sarcopenia were twice as likely to develop end-stage kidney disease (hazard ratio: 1.98; 1.45 to 2.70, <i>P</i> &lt; 0.001). Future studies on cachexia and sarcopenia in patients with CKD are needed to report rigorously defined cachexia concerning kidney function. Moreover, in studies on sarcopenia with CKD, it is desirable to accumulate studies using cystatin C to accurately estimate kidney function.</p>","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1589-1595"},"PeriodicalIF":8.9,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6026390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer 患者报告的行走4米和洗澡的能力:晚期癌症患者新的临床终点和生存预测因素
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-24 DOI: 10.1002/jcsm.13247
Markus S. Anker, Alessia Lena, Eric J. Roeland, Jan Porthun, Sebastian Schmitz, Sara Hadzibegovic, Philipp Sikorski, Ursula Wilkenshoff, Ann-Kathrin Fr?hlich, Luisa Valentina Ramer, Matthias Rose, Jan Eucker, Tienush Rassaf, Matthias Totzeck, Lorenz H. Lehmann, Stephan von Haehling, Andrew J.S. Coats, Tim Friede, Javed Butler, Stefan D. Anker, Hanno Riess, Ulf Landmesser, Lars Bullinger, Ulrich Keller, Johann Ahn
{"title":"Patient-reported ability to walk 4 m and to wash: New clinical endpoints and predictors of survival in patients with pre-terminal cancer","authors":"Markus S. Anker,&nbsp;Alessia Lena,&nbsp;Eric J. Roeland,&nbsp;Jan Porthun,&nbsp;Sebastian Schmitz,&nbsp;Sara Hadzibegovic,&nbsp;Philipp Sikorski,&nbsp;Ursula Wilkenshoff,&nbsp;Ann-Kathrin Fr?hlich,&nbsp;Luisa Valentina Ramer,&nbsp;Matthias Rose,&nbsp;Jan Eucker,&nbsp;Tienush Rassaf,&nbsp;Matthias Totzeck,&nbsp;Lorenz H. Lehmann,&nbsp;Stephan von Haehling,&nbsp;Andrew J.S. Coats,&nbsp;Tim Friede,&nbsp;Javed Butler,&nbsp;Stefan D. Anker,&nbsp;Hanno Riess,&nbsp;Ulf Landmesser,&nbsp;Lars Bullinger,&nbsp;Ulrich Keller,&nbsp;Johann Ahn","doi":"10.1002/jcsm.13247","DOIUrl":"https://doi.org/10.1002/jcsm.13247","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Maintaining the ability to perform self-care is a critical goal in patients with cancer. We assessed whether the patient-reported ability to walk 4 m and wash oneself predict survival in patients with pre-terminal cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed a prospective observational study on 169 consecutive hospitalized patients with cancer (52% female, 64 ± 12 years) and an estimated 1–12 months prognosis at an academic, inpatient palliative care unit. Patients answered functional questions for ‘today’, ‘last week’, and ‘last month’, performed patient-reported outcomes (PROs), and physical function assessments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Ninety-two (54%) patients reported the ability to independently walk 4 m and 100 (59%) to wash ‘today’. The median number of days patients reported the ability to walk 4 m and wash were 6 (IQR 0–7) and 7 (0–7) days (‘last week’); and 27 (5–30) and 26 (10–30) days (‘last month’). In the last week, 32% of patients were unable to walk 4 m on every day and 10% could walk on 1–3 days; 30% were unable to wash on every day and 10% could wash on 1–3 days. In the last months, 14% of patients were unable to walk 4 m on every day and 10% could only walk on 1–10 days; 12% were unable to wash on every day and 11% could wash on 1–10 days. In patients who could walk ‘today’ average 4 m gait speed was 0.78 ± 0.28 m/s. Patients who reported impaired walking and washing experienced more symptoms (dyspnoea, exertion, and oedema) and decreased physical function (higher Eastern Cooperative Oncology Group Performance Status, and lower Karnofsky Performance Status and hand-grip strength [unable vs. able to walk ‘today’: 205 ± 87 vs. 252 ± 78 Newton, <i>P</i> = 0.001; unable vs. able to wash ‘today’: 204 ± 86 vs. 250 ± 80 Newton, <i>P</i> = 0.001]). During the 27 months of observation, 152 (90%) patients died (median survival 46 days). In multivariable Cox proportional hazards regression analyses, all tested parameters were independent predictors of survival: walking 4 m ‘today’ (HR 0.63, <i>P</i> = 0.015), ‘last week’ (per 1 day: HR 0.93, <i>P</i> = 0.011), ‘last month’ (per 1 day: HR 0.98, <i>P</i> = 0.012), 4 m gait speed (per 1 m/s: HR 0.45, <i>P</i> = 0.002), and washing ‘today’ (HR 0.67, <i>P</i> = 0.024), ‘last week (per 1 day HR 0.94, p=0.019), and ‘last month’ (per 1 day HR 0.99, <i>P</i> = 0.040). Patients unable to walk and wash experienced the shortest survival and most reduced functional status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 ","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1670-1681"},"PeriodicalIF":8.9,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13247","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5807879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of the prognostic value of computed tomography-derived body composition in patients undergoing endovascular aneurysm repair 对行血管内动脉瘤修复术患者的ct体成分预测价值的评价
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-23 DOI: 10.1002/jcsm.13262
Nicholas A. Bradley, Amy Walter, Ross Dolan, Alasdair Wilson, Tamim Siddiqui, Campbell S.D. Roxburgh, Donald C. McMillan, Graeme J.K. Guthrie
{"title":"Evaluation of the prognostic value of computed tomography-derived body composition in patients undergoing endovascular aneurysm repair","authors":"Nicholas A. Bradley,&nbsp;Amy Walter,&nbsp;Ross Dolan,&nbsp;Alasdair Wilson,&nbsp;Tamim Siddiqui,&nbsp;Campbell S.D. Roxburgh,&nbsp;Donald C. McMillan,&nbsp;Graeme J.K. Guthrie","doi":"10.1002/jcsm.13262","DOIUrl":"https://doi.org/10.1002/jcsm.13262","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Endovascular aneurysm repair (EVAR) is the most common mode of repair of abdominal aortic aneurysms (AAA) in the UK. EVAR ranges from standard infrarenal repair to complex fenestrated and branched EVAR (F/B-EVAR). Sarcopenia is defined by lower muscle mass and function, which is associated with inferior perioperative outcomes. Computed tomography-derived body composition analysis offers prognostic value in patients with cancer. Several authors have evaluated the role of body composition analysis in predicting outcomes in patients undergoing EVAR; however, the evidence base is limited by heterogeneous methodology.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Six hundred seventy-four consecutive patients (58 (8.6%) female, mean (SD) age 74.4 (6.8) years) undergoing EVAR and F/B-EVAR at three large tertiary centres were retrospectively recruited. Subcutaneous and visceral fat indices (SFI and VFI), psoas and skeletal muscle indices, and skeletal muscle density were measured at the L3 vertebral level from pre-operative computed tomographies. The maximally selected rank statistic technique was used to define optimal thresholds to predict mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>There were 191 deaths during the median follow-up period of 60.0 months. Mean (95% CI) survival in the low SMI versus high SMI subgroups was 62.6 (58.5–66.7) versus 82.0 (78.7–85.3) months (<i>P</i> &lt; 0.001). Mean (95% CI) survival in the low SFI versus high SFI subgroups was 56.4 (48.2–64.7) versus 77.1 (74.2–80.1) months (<i>P</i> &lt; 0.001). One-year mortality in the low SMI versus high SMI subgroups was 10% versus 3% (<i>P</i> &lt; 0.001). Low SMI was associated with increased odds of one-year mortality (OR 3.19, 95% CI 1.60–6.34, <i>P</i> &lt; 0.001). Five-year mortality in the low SMI versus high SMI subgroups was 55% versus 28% (<i>P</i> &lt; 0.001). Low SMI was associated with increased odds of five-year mortality (OR 1.54, 95% CI 1.11–2.14, <i>P</i> &lt; 0.01). On multivariate analysis of all patients, low SFI (HR 1.90, 95% CI 1.30–2.76, <i>P</i> &lt; 0.001) and low SMI (HR 1.88, 95% CI 1.34–2.63, <i>P</i> &lt; 0.001) were associated with poorer survival. On multivariate analysis of asymptomatic AAA patients, low SFI (HR 1.54, 95% CI 1.01–2.35, <i>P</i> &lt; 0.05) and low SMI (HR 1.71, 95% CI 1.20–2.42, <i>P</i> &lt; 0.01) were associated with poorer survival.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Low SMI and SFI are associated with poorer long-term survival following EVAR and F/B-EVAR. The relation","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1836-1847"},"PeriodicalIF":8.9,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13262","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5688973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome 面肩肱骨肌营养不良定量肌肉磁共振成像的五年随访研究:与临床结果的联系
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-23 DOI: 10.1002/jcsm.13250
Sanne C.C. Vincenten, Karlien Mul, Dani?l van As, Julia J. Jansen, Linda Heskamp, Arend Heerschap, Baziel G.M. van Engelen, Nicol C. Voermans
{"title":"Five-year follow-up study on quantitative muscle magnetic resonance imaging in facioscapulohumeral muscular dystrophy: The link to clinical outcome","authors":"Sanne C.C. Vincenten,&nbsp;Karlien Mul,&nbsp;Dani?l van As,&nbsp;Julia J. Jansen,&nbsp;Linda Heskamp,&nbsp;Arend Heerschap,&nbsp;Baziel G.M. van Engelen,&nbsp;Nicol C. Voermans","doi":"10.1002/jcsm.13250","DOIUrl":"https://doi.org/10.1002/jcsm.13250","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>It is unclear how changes in quantitative muscle magnetic resonance imaging (MRI) relate to changes in clinical outcome in facioscapulohumeral muscular dystrophy (FSHD), although this information is crucial for optimal use of MRI as imaging biomarker in trials. We therefore assessed muscle MRI and clinical outcome measures in a large longitudinal prospective cohort study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>All patients were assessed by MRI at baseline and at 5-year follow-up, employing 2pt-Dixon and turbo inversion recovery magnitude (TIRM) sequences, after which fat fraction and TIRM positivity of 19 leg muscles were determined bilaterally. The MRI compound score (CoS) was defined as the mean fat fraction of all muscles weighted for cross-sectional area. Clinical outcome measures included the Ricci-score, FSHD clinical score (FSHD-CS), MRC sumscore (MRC-SS), and motor-function-measure (MFM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We included 105 FSHD patients [mean age 54 ± 14 years, median Ricci-score 7 (range 0–10)]. The median change over 5 years' time in the MRI-CoS was 2.0% (range −4.6 to +12.1; <i>P</i> &lt; 0.001). The median change over 5 years' time in clinical outcome measures was small in all measures, with <i>z</i>-scores ranging from 5.0 to 7.2 (<i>P</i> &lt; 0.001). The change in MRI-CoS correlated with change in FSHD-CS and Ricci-score (ρ = 0.25, respectively; ρ = 0.23, <i>P</i> &lt; 0.05). The largest median increase in MRI-CoS was seen in baseline subgroups with an MRI-CoS 20–40% (6.1%), with ≥2 TIRM positive muscles (3.5%) or with an FSHD-CS 5–10 (3.1%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This 5-year study showed significant changes in MRI and clinical outcome measures and a significant correlation between changes in MRI-CoS and changes in clinical outcome measures. In addition, we identified subgroups of patients that are most prone to radiological disease progression. This knowledge further establishes quantitative MRI parameters as prognostic biomarkers in FSHD and as efficacy biomarkers in upcoming clinical trials.</p>\u0000 </section>\u0000 </div>","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1695-1706"},"PeriodicalIF":8.9,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13250","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5768401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Validation of a telephone-based administration of the simplified nutritional appetite questionnaire 简化营养食欲问卷电话管理的验证
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-22 DOI: 10.1002/jcsm.13264
Binh Duong Thai, Jürgen M. Bauer, Annette Eidam, Jane Durga, Stefan Grund, Thomas Mross, Petra Benzinger
{"title":"Validation of a telephone-based administration of the simplified nutritional appetite questionnaire","authors":"Binh Duong Thai,&nbsp;Jürgen M. Bauer,&nbsp;Annette Eidam,&nbsp;Jane Durga,&nbsp;Stefan Grund,&nbsp;Thomas Mross,&nbsp;Petra Benzinger","doi":"10.1002/jcsm.13264","DOIUrl":"https://doi.org/10.1002/jcsm.13264","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Anorexia of aging is characterized by an age-associated reduction of appetite, whose aetiology in most cases is multifactorial and which often triggers malnutrition. The Simplified Nutritional Appetite Questionnaire (SNAQ) is an established screening tool. This study aimed to investigate reliability, validity, and feasibility of its telephone administration (T-SNAQ) in German community-dwelling older adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional single-centre study recruited participants from April 2021 to September 2021. First, the SNAQ was translated into German according to an established methodology. After translation, reliability, construct validity, and feasibility of the T-SNAQ were analysed. A convenience sample of community-dwelling older adults aged ≥70 years was recruited. The following measurements were applied to all participants: T-SNAQ, Mini Nutritional Assessment – Short Form (MNA-SF), six-item Katz index of independence in activities of daily living (ADL), eight-item Lawton instrumental activities of daily living (IADL), telephone Montreal Cognitive Assessment (T-MoCA); FRAIL scale, Geriatric Depression Scale (GDS-15) and Charlson co-morbidity index as well as daily caloric and protein intake.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>One hundred twenty participants (59.2% female) with a mean age of 78.0 ± 5.8 years were included in the present study. The percentage of participants identified with poor appetite based on T-SNAQ was 20.8% (<i>n</i> = 25). T-SNAQ showed a good internal reliability with a Cronbach's alpha coefficient of 0.64 and a good test–retest reliability [intraclass coefficient of 0.95 (<i>P</i> &lt; 0.05)]. Regarding construct validity, T-SNAQ was significantly positively correlated with MNA-SF (<i>r</i> = 0.213), T-MoCA (<i>r</i> = 0.225), daily energy (<i>r</i> = 0.222) and protein intake (<i>r</i> = 0.252) (<i>P</i> &lt; 0.05). It also demonstrated a significant negative association with GDS-15 (<i>r</i> = −0.361), FRAIL scale (<i>r</i> = −0.203) and Charlson co-morbidity index (<i>r</i> = −0.272). Regarding applicability, the mean time for T-SNAQ was 95 s and completion rate was 100%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The T-SNAQ is a feasible screening instrument for anorexia of aging in community-dwelling older adults via telephone interviews.</p>\u0000 </section>\u0000 </div>","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1848-1854"},"PeriodicalIF":8.9,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13264","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5753608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low muscle mass, malnutrition, sarcopenia, and associations with survival in adults with cancer in the UK Biobank cohort 在英国生物银行队列中,低肌肉量、营养不良、肌肉减少症与成人癌症患者生存率的关系
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-22 DOI: 10.1002/jcsm.13256
Nicole Kiss, Carla M. Prado, Robin M. Daly, Linda Denehy, Lara Edbrooke, Brenton J. Baguley, Steve F. Fraser, Abbas Khosravi, Gavin Abbott
{"title":"Low muscle mass, malnutrition, sarcopenia, and associations with survival in adults with cancer in the UK Biobank cohort","authors":"Nicole Kiss,&nbsp;Carla M. Prado,&nbsp;Robin M. Daly,&nbsp;Linda Denehy,&nbsp;Lara Edbrooke,&nbsp;Brenton J. Baguley,&nbsp;Steve F. Fraser,&nbsp;Abbas Khosravi,&nbsp;Gavin Abbott","doi":"10.1002/jcsm.13256","DOIUrl":"https://doi.org/10.1002/jcsm.13256","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Low muscle mass (MM) is a common component of cancer-related malnutrition and sarcopenia, conditions that are all independently associated with an increased risk of mortality. This study aimed to (1) compare the prevalence of low MM, malnutrition, and sarcopenia and their association with survival in adults with cancer from the UK Biobank and (2) explore the influence of different allometric scaling (height [m<sup>2</sup>] or body mass index [BMI]) on low MM estimates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Participants in the UK Biobank with a cancer diagnosis within 2 years of the baseline assessment were identified. Low MM was estimated by appendicular lean soft tissue (ALST) from bioelectrical impedance analysis derived fat-free mass. Malnutrition was determined using the Global Leadership in Malnutrition criteria. Sarcopenia was defined using the European Working Group on Sarcopenia in Older People criteria (version 2). All-cause mortality was determined from linked national mortality records. Cox-proportional hazards models were fitted to estimate the effect of low MM, malnutrition, and sarcopenia on all-cause mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 4122 adults with cancer (59.8 ± 7.1 years; 49.2% male) were included. Prevalence of low MM (8.0% vs. 1.7%), malnutrition (11.2% vs. 6.2%), and sarcopenia (1.4% vs. 0.2%) was higher when MM was adjusted using ALST/BMI compared with ALST/height<sup>2</sup>, respectively. Low MM using ALST/BMI identified more cases in participants with obesity (low MM 56.3% vs. 0%; malnutrition 50% vs. 18.5%; sarcopenia 50% vs. 0%). During a median 11.2 (interquartile range: 10.2, 12.0) years of follow up, 901 (21.7%) of the 4122 participants died, and of these, 744 (82.6%) deaths were cancer-specific All conditions were associated with a higher hazard of mortality using either method of MM adjustment: low MM (ALST/height<sup>2</sup>: HR 1.9 [95% CI 1.3, 2.8], <i>P</i> = 0.001; ALST/BMI: HR 1.3 [95% CI 1.1, 1.7], <i>P</i> = 0.005; malnutrition (ALST/height<sup>2</sup>: HR 2.5 [95% CI 1.1, 1.7], <i>P</i> = 0.005; ALST/BMI: HR 1.3 [95% CI 1.1, 1.7], <i>P</i> = 0.005; sarcopenia (ALST/height<sup>2</sup>: HR 2.9 [95% CI 1.3, 6.5], <i>P</i> = 0.013; ALST/BMI: HR 1.6 [95% CI 1.0, 2.4], <i>P</i> = 0.037).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In adults with cancer, malnutrition was more common than low MM or sarcopenia, although all conditions were associated with a higher mortality risk, regardless of the method of adjusting for MM. In co","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1775-1788"},"PeriodicalIF":8.9,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13256","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5777908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Slo1 deficiency impaired skeletal muscle regeneration and slow-twitch fibre formation Slo1缺乏损害骨骼肌再生和慢肌纤维形成
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-22 DOI: 10.1002/jcsm.13253
Chao Xia, Yonghui Wang, Tianyuan Jiang, Yan Hu, Yang Chen, Xinrun Ma, Xuemei Zhang, Yanhong Gao
{"title":"Slo1 deficiency impaired skeletal muscle regeneration and slow-twitch fibre formation","authors":"Chao Xia,&nbsp;Yonghui Wang,&nbsp;Tianyuan Jiang,&nbsp;Yan Hu,&nbsp;Yang Chen,&nbsp;Xinrun Ma,&nbsp;Xuemei Zhang,&nbsp;Yanhong Gao","doi":"10.1002/jcsm.13253","DOIUrl":"https://doi.org/10.1002/jcsm.13253","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>It has been observed that Slo1 knockout mice have reduced motor function, and people with certain Slo1 mutations have movement problems, but there is no answer whether the movement disorder is caused by the loss of Slo1 in the nervous system, or skeletal muscle, or both. Here, to ascertain in which tissues Slo1 functions to regulate motor function and offer deeper insight in treating related movement disorder, we generated skeletal muscle-specific Slo1 knockout mice, studied the functional changes in Slo1-deficient skeletal muscle and explored the underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used skeletal muscle-specific Slo1 knockout mice (Myf5-Cre; Slo1<sup>flox/flox</sup> mice, called CKO) as in vivo models to examine the role of Slo1 in muscle growth and muscle regeneration. The forelimb grip strength test was used to assess skeletal muscle function and treadmill exhaustion test was used to test whole-body endurance. Mouse primary myoblasts derived from CKO (myoblast/CKO) mice were used to extend the findings to in vitro effects on myoblast differentiation and fusion. Quantitative real-time PCR, western blot and immunofluorescence approaches were used to analyse Slo1 expression during myoblast differentiation and muscle regeneration. To investigate the involvement of genes in the regulation of muscle dysfunction induced by Slo1 deletion, RNA-seq analysis was performed in primary myoblasts. Immunoprecipitation and mass spectrometry were used to identify the protein interacting with Slo1. A dual-luciferase reporter assay was used to identify whether Slo1 deletion affects NFAT activity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We found that the body weight and size of CKO mice were not significantly different from those of Slo1<sup>flox/flox</sup> mice (called WT). Deficiency of Slo1 in muscles leads to reduced endurance (~30% reduction, <i>P</i> &lt; 0.05) and strength (~30% reduction, <i>P</i> &lt; 0.001). Although there was no difference in the general morphology of the muscles, electron microscopy revealed a considerable reduction in the content of mitochondria in the soleus muscle (~40% reduction, <i>P</i> &lt; 0.01). We found that Slo1 was expressed mainly on the cell membrane and showed higher expression in slow-twitch fibres. Slo1 protein expression is progressively reduced during muscle postnatal development and regeneration after injury, and the expression is strongly reduced during myoblast differentiation. Slo1 deletion impaired myoblast differentiation and slow-twitch fibre formation. Mechanistically, RNA-seq analysis showed that Slo1 influences the expression of g","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1737-1752"},"PeriodicalIF":8.9,"publicationDate":"2023-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13253","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5777911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomarkers and mechanisms associated with cancer-induced cardiac cachexia: A systematic review 与癌症诱导的心脏恶病质相关的生物标志物和机制:系统综述
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-21 DOI: 10.1002/jcsm.13267
Lisa Bagnall, Oliver Grundmann, Marilyn G. Teolis, Saun-Joo L. Yoon
{"title":"Biomarkers and mechanisms associated with cancer-induced cardiac cachexia: A systematic review","authors":"Lisa Bagnall,&nbsp;Oliver Grundmann,&nbsp;Marilyn G. Teolis,&nbsp;Saun-Joo L. Yoon","doi":"10.1002/jcsm.13267","DOIUrl":"https://doi.org/10.1002/jcsm.13267","url":null,"abstract":"<p>Cancer cachexia is a severe multifactorial syndrome<span><sup>1</sup></span> that affects up to 80% of patients with advanced cancer, causing death in 20–80% with no effective treatments.<span><sup>2, 3</sup></span> It causes multi-organ alteration and loss of skeletal and cardiac (myocardium) muscle mass.<span><sup>4, 5</sup></span> Cardiac muscle wasting may result from cardiac protein loss associated with increased oxygen consumption and energy expenditure, resulting in cardiac insufficiency.<span><sup>5</sup></span> It is hypothesized that significant tissue inflammation and oxidative stress during cancer progression cause cardiac wasting-associated cardiomyopathy, such as a thinned ventricular wall, local tissue hypoxia and arrhythmias.<span><sup>6</sup></span> This review provided available evidence of cancer-induced cardiac cachexia in human and non-human models by examining biomarkers and the contributing factors to the development and progression of cardiac cachexia. Investigation of the potential biomarkers affecting cardiac muscle wasting is essential for improving patient outcomes.</p><p>Our knowledge about the causes of cardiac cachexia in cancer remains limited and the possible mechanisms have only been explored in animal studies to date. A better understanding of the pathophysiology of cardiac cachexia may help to determine if targeted therapies can effectively block the upregulation of various genes and cytokines that initiate and facilitate cancer-induced cardiac cachexia. Understanding the distinct nature of cancer-related cardiac cachexia and what distinguishes it from other causes may also lead to finding targeted, effective treatments. Treating cardiac cachexia early and before clinical changes are noted may improve overall cardiac function and lead to better patient outcomes.</p><p>The authors have no conflicts of interest.</p>","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1900-1905"},"PeriodicalIF":8.9,"publicationDate":"2023-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5656013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of muscle wasting with mortality risk among adults: A systematic review and meta-analysis of prospective studies 成人肌肉萎缩与死亡风险的关系:前瞻性研究的系统回顾和荟萃分析
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-20 DOI: 10.1002/jcsm.13263
Huan-Huan Zhou, Yuxiao Liao, Zhao Peng, Fang Liu, Qi Wang, Wei Yang
{"title":"Association of muscle wasting with mortality risk among adults: A systematic review and meta-analysis of prospective studies","authors":"Huan-Huan Zhou,&nbsp;Yuxiao Liao,&nbsp;Zhao Peng,&nbsp;Fang Liu,&nbsp;Qi Wang,&nbsp;Wei Yang","doi":"10.1002/jcsm.13263","DOIUrl":"https://doi.org/10.1002/jcsm.13263","url":null,"abstract":"<p>The relationship between muscle wasting and mortality risk in the general population remains unclear. Our study was conducted to examine and quantify the associations between muscle wasting and all-cause and cause-specific mortality risks. PubMed, Web of Science and Cochrane Library were searched until 22 March 2023 for main data sources and references of retrieved relevant articles. Prospective studies investigating the associations of muscle wasting with risks of all-cause and cause-specific mortality in the general population were eligible. A random-effect model was used to calculate the pooled relative risk (RR) and 95% confidence intervals (CIs) for the lowest versus normal categories of muscle mass. Subgroup analyses and meta-regression were performed to investigate the potential sources of heterogeneities among studies. Dose–response analyses were conducted to evaluate the relationship between muscle mass and mortality risk. Forty-nine prospective studies were included in the meta-analysis. A total of 61 055 deaths were ascertained among 878 349 participants during the 2.5- to 32-year follow-up. Muscle wasting was associated with higher mortality risks of all causes (RR = 1.36, 95% CI, 1.28 to 1.44, <i>I</i><sup>2</sup> = 94.9%, 49 studies), cardiovascular disease (CVD) (RR = 1.29, 95% CI, 1.05 to 1.58, <i>I</i><sup>2</sup> = 88.1%, 8 studies), cancer (RR = 1.14, 95% CI, 1.02 to 1.27, <i>I</i><sup>2</sup> = 38.7%, 3 studies) and respiratory disease (RR = 1.36, 95% CI, 1.11 to 1.67, <i>I</i><sup>2</sup> = 62.8%, 3 studies). Subgroup analyses revealed that muscle wasting, regardless of muscle strength, was significantly associated with a higher all-cause mortality risk. Meta-regression showed that risks of muscle wasting-related all-cause mortality (<i>P</i> = 0.06) and CVD mortality (<i>P</i> = 0.09) were lower in studies with longer follow-ups. An approximately inverse linear dose–response relationship was observed between mid-arm muscle circumference and all-cause mortality risk (<i>P</i> &lt; 0.01 for non-linearity). Muscle wasting was associated with higher mortality risks of all causes, CVD, cancer and respiratory disease in the general population. Early detection and treatment for muscle wasting might be crucial for reducing mortality risk and promoting healthy longevity.</p>","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1596-1612"},"PeriodicalIF":8.9,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13263","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5779216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
SPSB1-mediated inhibition of TGF-β receptor-II impairs myogenesis in inflammation spsb1介导的TGF-β受体ii抑制可损害炎症中的肌生成
IF 8.9 1区 医学
Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2023-05-20 DOI: 10.1002/jcsm.13252
Yi Li, Niklas D?rmann, Bj?rn Brinschwitz, Melanie Kny, Elisa Martin, Kirsten Bartels, Ning Li, Priyanka Voori Giri, Stefan Schwanz, Michael Boschmann, Susanne Hille, Britta Fielitz, Tobias Wollersheim, Julius Grunow, Stephan B. Felix, Steffen Weber-Carstens, Friedrich C. Luft, Oliver J. Müller, Jens Fielitz
{"title":"SPSB1-mediated inhibition of TGF-β receptor-II impairs myogenesis in inflammation","authors":"Yi Li,&nbsp;Niklas D?rmann,&nbsp;Bj?rn Brinschwitz,&nbsp;Melanie Kny,&nbsp;Elisa Martin,&nbsp;Kirsten Bartels,&nbsp;Ning Li,&nbsp;Priyanka Voori Giri,&nbsp;Stefan Schwanz,&nbsp;Michael Boschmann,&nbsp;Susanne Hille,&nbsp;Britta Fielitz,&nbsp;Tobias Wollersheim,&nbsp;Julius Grunow,&nbsp;Stephan B. Felix,&nbsp;Steffen Weber-Carstens,&nbsp;Friedrich C. Luft,&nbsp;Oliver J. Müller,&nbsp;Jens Fielitz","doi":"10.1002/jcsm.13252","DOIUrl":"https://doi.org/10.1002/jcsm.13252","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Sepsis-induced intensive care unit-acquired weakness (ICUAW) features profound muscle atrophy and attenuated muscle regeneration related to malfunctioning satellite cells. Transforming growth factor beta (TGF-β) is involved in both processes. We uncovered an increased expression of the TGF-β receptor II (TβRII)-inhibitor SPRY domain-containing and SOCS-box protein 1 (SPSB1) in skeletal muscle of septic mice. We hypothesized that SPSB1-mediated inhibition of TβRII signalling impairs myogenic differentiation in response to inflammation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We performed gene expression analyses in skeletal muscle of cecal ligation and puncture- (CLP) and sham-operated mice, as well as <i>vastus lateralis</i> of critically ill and control patients. Pro-inflammatory cytokines and specific pathway inhibitors were used to quantitate <i>Spsb1</i> expression in myocytes. Retroviral expression plasmids were used to investigate the effects of SPSB1 on TGF-β/TβRII signalling and myogenesis in primary and immortalized myoblasts and differentiated myotubes. For mechanistical analyses we used coimmunoprecipitation, ubiquitination, protein half-life, and protein synthesis assays. Differentiation and fusion indices were determined by immunocytochemistry, and differentiation factors were quantified by qRT-PCR and Western blot analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p><i>SPSB1</i> expression was increased in skeletal muscle of ICUAW patients and septic mice. Tumour necrosis factor (TNF), interleukin-1β (IL-1β), and IL-6 increased the <i>Spsb1</i> expression in C2C12 myotubes. TNF- and IL-1β-induced <i>Spsb1</i> expression was mediated by NF-κB, whereas IL-6 increased the <i>Spsb1</i> expression via the glycoprotein 130/JAK2/STAT3 pathway. All cytokines reduced myogenic differentiation. SPSB1 avidly interacted with TβRII, resulting in TβRII ubiquitination and destabilization. SPSB1 impaired TβRII-Akt-Myogenin signalling and diminished protein synthesis in myocytes. Overexpression of SPSB1 decreased the expression of early (<i>Myog</i>, <i>Mymk</i>, <i>Mymx</i>) and late (<i>Myh1</i>, <i>3</i>, <i>7</i>) differentiation-markers. As a result, myoblast fusion and myogenic differentiation were impaired. These effects were mediated by the SPRY- and SOCS-box domains of SPSB1. Co-expression of SPSB1 with Akt or Myogenin reversed the inhibitory effects of SPSB1 on protein synthesis and myogenic differentiation. Downregulation of <i>Spsb1</i> by AAV9-mediated shRNA attenuated muscle weight loss and atrophy gene expression in skeletal muscle of septic mice.</p>\u0000 </section>\u0000 ","PeriodicalId":186,"journal":{"name":"Journal of Cachexia, Sarcopenia and Muscle","volume":"14 4","pages":"1721-1736"},"PeriodicalIF":8.9,"publicationDate":"2023-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.13252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5779221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信